Abstract
Southern U.S. communities experience high HIV incidence and substance use prevalence, yet low PrEP uptake. Providers (N = 191) completed a survey about willingness to refer/link clients with HIV risk to PrEP. Through in-depth interviews, 12 directors (5 sexually transmitted infection [STI] clinics; 5 syringe services programs [SSPs]; 2 substance use treatment programs [SUTPs]) described multi-level factors that contextualized provider willingness. Providers were more willing to refer/link clients with unspecified HIV risk and men who have sex with men to PrEP vs. other populations. SUTP (vs. SSP) providers were less willing to refer/link clients with unspecified risk and men who use opioids. Older (vs. younger) providers were less willing, and more (vs. less) experienced providers more willing to refer/link to PrEP. Directors described facilitators (e.g., comprehensive health center partnerships) and barriers (e.g., provider stigma toward people who use drugs) to PrEP implementation. Findings highlight the importance of considering multi-level factors in PrEP implementation.
Keywords: HIV pre-exposure prophylaxis, mixed methods, PrEP implementation, people who use drugs
The Southern U.S. comprised 53% of new HIV diagnoses in 2022, despite comprising only 38% of the U.S. population (AIDSvu, 2024b). Florida, Louisiana, Georgia, Mississippi, and Tennessee are ranked among the top seven states in new HIV diagnoses (ranging from 20.3/100,000 to 29.3/100,000 people) (Centers for Disease Control and Prevention [CDC], 2023). The 2022–2025 National HIV/AIDS Strategy has emphasized focusing on the Southern U.S. to address high HIV incidence regions (The White House, 2021). In particular, the National Strategy seeks to reduce health disparities and inequities, including the disproportionate burden of HIV affecting the Southern U.S.
Most Americans at risk for or living with HIV rely on Medicaid for HIV-related treatments and services (Dawson et al., 2023). Many Southern states rejected Medicaid expansion through the Affordable Care Act, contributing to diminished access to HIV treatment and prevention, i.e., pre-exposure prophylaxis (PrEP) (Kates et al., 2021). Further, social determinants of health (e.g., poverty; discrimination based on gender, race, and sexual identity; medical mistrust) have been found to contribute to persistently higher HIV incidence in the Southern U.S. (Sprague & Simon, 2021).
Since its Food and Drug Administration (FDA) approval in 2012, PrEP has been shown to be 99% and 74% effective at reducing HIV transmission through sexual contact and injection drug use, respectively (HIV.gov, 2024). Currently available PrEP regimens include daily oral PrEP; injectable PrEP every two months (FDA-approved, but not widely available); and off-label (not FDA-approved) 2-1-1 PrEP (i.e., taking PrEP on-demand, with two pills at least two hours prior to sex and one pill 24hours later). Regimen recommendations vary depending on potential routes of HIV transmission (e.g., sexual transmission vs. injection drug use transmission) (CDC, 2025). Despite its widespread availability and proven track record over more than a decade, PrEP remains underutilized, especially in the Southern states. In 2022, people in the Southern U.S. comprised only 38% of all people using PrEP (AIDSvu, 2024a).
Medical (e.g., MDs; nurses) and behavioral health providers (e.g., social workers; mental health counselors; hereafter referred to as “providers”) play a crucial role in building PrEP awareness, providing education, and prescribing or linking clients to medication. However, providers sometimes lack knowledge about PrEP or may have misconceptions and mistrust of clients; both factors may hinder their willingness to prescribe or link clients to PrEP (Dubov et al., 2023; Waldron et al., 2024). The CDC recommends that PrEP be widely promoted and offered in all primary care settings (CDC, 2021). In reality, only 28% to 45% of providers with prescribing privileges have expressed willingness to prescribe PrEP (Jones et al., 2021; Petroll et al., 2017; Walsh & Petroll, 2017); even fewer report having actually prescribed it (Jones et al., 2021; Petroll et al., 2017).
Barriers to provider willingness include PrEP not being in their purview of practice; lack of confidence in ability to identify clients at risk for HIV; stigma toward people who use drugs (PWUD); and low level of comfort with discussing sexual health (Biello et al., 2021; Dubov et al., 2023; Moore et al., 2020; Waldron et al., 2024). Research has also found that providers’ willingness to link clients to PrEP may vary by clients’ demographic backgrounds. For example, some research has indicated that providers are less comfortable working with transgender clients than with cisgender clients (Moore et al., 2020). In addition, stigma and biases toward cisgender women, PWUD, and more specifically, people who inject drugs (PWID) may further impact providers’ willingness to link clients to PrEP (Dubov et al., 2023; Waldron et al., 2024). Newer research has found that among primary care providers in the South, providers of color (vs. white providers) and those in urban and suburban (vs. rural) settings were more willing to prescribe PrEP (Traylor et al., 2024). According to providers, key barriers to prescribing PrEP include not having enough time to do so; inadequate PrEP training; and stigma toward clients in need of PrEP. Providers have also highlighted their clients’ insufficient insurance coverage as another main barrier to PrEP (Traylor et al., 2024).
There is a dearth of research on attitudes and willingness to link PWUD to PrEP among non-medical service providers (e.g., behavioral health, case management, etc.). Research outside the Southern U.S. has indicated gaps in understanding willingness of non-medical providers to connect their clients to PrEP (Jaiswal et al., 2021). Understanding these providers’ attitudes toward PrEP in community-based organizations (CBOs) is particularly important. CBOs are often service hubs for PWUD and other populations at high risk for HIV and may be ideal settings for PrEP provision. Yet, historically CBOs have been less likely to offer PrEP services than other healthcare settings (Vanhamel et al., 2020).
Purpose
Given these gaps in the literature, the purpose of this mixed methods study was: (1) to characterize providers’ willingness to refer and link clients to PrEP by: (a) client population, (b) clinical setting, and (c) provider characteristics in CBOs in the Southern U.S.; and (2) to integrate directors’ understanding of their CBOs’ mission, infrastructure, and setting to contextualize provider willingness. Directors were uniquely positioned to discuss program planning, policy, funding, resources, staffing, training, and program sustainability. The following research questions were examined: (1) What factors are associated with providers’ (a) previous experience with PrEP, and (b) willingness to refer/link different clients to PrEP? (2) How do contextual (i.e., structural and macro-level) facilitators and barriers undergird provider willingness to refer/link clients to PrEP? Findings may advance our knowledge of best practices to reduce disparities in PrEP uptake, and ultimately HIV incidence, in the South.
Method
Study design
Data for this cross-sectional mixed methods study were collected from providers and directors as part of the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) 0082 study between September 2020 and July 2021. We used a concurrent mixed methods design, obtaining and analyzing quantitative provider surveys and qualitative director interviews contemporaneously, and leveraging findings from each in integrative interpretation (Creswell et al., 2003). Providers and directors worked at community-based sexually transmitted infection (STI) clinics, syringe services programs (SSPs), or outpatient substance use treatment programs (SUTPs) across eight cities in five states in the Southern U.S. (Florida, Georgia, Louisiana, Mississippi, and Tennessee). These states had the highest HIV incidence at the time of study approval (Centers for Disease Control and Prevention, 2017a, 2017b).
The overall study included five STI clinics, five SSPs, and two SUTPs. An additional site within an HIV testing, risk assessment, and prevention clinic bridged patients to substance use services, as well as mental health and medical services. For quantitative analyses of provider surveys, that site was classified as a sixth STI clinic given that its mission and services were closer to those described for study STI clinics. However, qualitative findings from that site were not included in the current study given that its primary focus was neither STI nor substance use treatment.
The Human Subjects Division at the University of Washington deemed this study as human subjects research that qualifies for exempt status (Category 2) and, thus, exempt from federal human subjects regulations. Detailed information on study design, recruitment, and procedures, as well as findings regarding client PrEP willingness have been published elsewhere (Ertl et al., 2025; Hatch et al., 2024; Paschen-Wolff et al., 2024; Tross et al., 2025).
The STI clinic sample for the current study consisted of sites across two states with diverse organizational identity and infrastructure. These included two STI clinics within large community health centers; one within a multi-service HIV testing and prevention agency; one within a freestanding LGBTQ+ youth-centered CBO; and one STI clinic within a large substance use treatment network. The additional site classified as an STI clinic for the quantitative survey analyses only was located within an academic medical center.
The five SSP study sites were harm reduction programs located across four states. These were: two freestanding SSP sites; one SSP within an HIV- and substance use-centered harm reduction and support services program; and one SSP within a community health center. The fifth SSP—a centerpiece of research on integrated substance use and HIV/HCV medical services for people with high HIV risk who use drugs—was based in an academic medical center.
The two SUTPs included in the current study were in the same state. Both provided substance use treatment proper and were housed within well-established, multi-site substance use treatment agencies.
Quantitative provider survey procedures
Directors identified eligible providers at their respective sites who: (a) delivered direct services (e.g., mental health services, care coordination/linkage, etc.) to clients at the site, (b) were 18 years of age or older, and (c) were able to speak and write in English. Directors (all of whom were also providers) completed the same survey. Director survey data are included with provider survey data in the quantitative analyses. At sites with more than 20 providers, a random selection process was used to invite up to 20 providers to complete the web-based survey. Random replacement was implemented for providers who did not respond to the survey after multiple prompts within one month. At sites with fewer than 20 providers, all providers were invited to participate. A third-party coordinating center not affiliated with the sites sent web-based survey links to the providers’ e-mail addresses. Providers were required to review a study information sheet and electronically agree to participate (without signature) prior to completing the confidential online survey. Providers received $50 as compensation for completing the approximately 45-minute survey.
In total, 394 providers received an email link to the survey. Of these, 228 providers agreed to participate, 222 completed the survey, and 31 were omitted (19 providers who could already prescribe PrEP; 12 who identified as transgender/non-binary [TGNB] due to very small cell sizes). The final quantitative sample size for the current study was 191 providers (range of 8 to 25 per site; Figure 1).
Figure 1.

Provider Survey Strobe Flow Diagram
Qualitative director interview procedures
Site directors at the 13 sites (n = 5 STI clinics, n = 5 SSPs, n = 2 SUTPs [additional site excluded from results as described above]) were invited via email by the study team to participate in an individual in-depth qualitative interview that took approximately 90 minutes. Study team members conducted interviews, which were recorded via a HIPAA-compliant Zoom platform. Inclusion criteria for site directors included that they: (a) had administrative and oversight knowledge of their agency, (b) were at least 18 years old, and (c) were able to speak and write in English. Directors indicated a verbal agreement to participate prior to beginning the qualitative interview and received $150 as compensation for their time.
Measures
Sociodemographic characteristics
Survey participants were asked to provide information on their sociodemographic backgrounds. Age was recorded in years. Experience in the field was reported in years and months. Gender included cisgender male, cisgender female, transgender male, transgender female, and non-binary. Race included Black/African American, white, and another race/multiracial. Ethnicity responses were non-Hispanic/Latine and Hispanic/Latine. Educational degrees were coded as High School/GED, College, Graduate, and Post-Graduate. Agency type included SSP, STI clinic, and SUTP. Position categories consisted of Administrator/Researcher, Medical Professional, Behavioral Health Provider, and Care Coordinator/Linkage.
PrEP awareness and experience
Three individual item measures adapted from Mimiaga and colleagues (2009) were used in the survey to describe PrEP awareness and two PrEP experience outcomes. After being given a definition of PrEP, participants were asked if they had ever heard of PrEP (0 = No, 1 = Yes). If so, they were asked if they had previously initiated a PrEP conversation with a client (0 = No, 1 = Yes) and if they had previously referred a client for PrEP (0 = No, 1 = Yes).
Willingness to refer/link different clients at high risk for HIV to PrEP
Provider willingness to refer or link six different client types at high risk for HIV to PrEP was assessed by questions adapted from Mimiaga and colleagues (2009). Client types included: (1) a client with high HIV risk (regardless of risk group); (2) men who have sex with men (MSM); (3) transgender men; (4) transgender women; (5) men who use opioids; and (6) women who use opioids. To assess provider willingness to refer/link: clients at high risk for HIV (population group unspecified); transgender men engaging in any HIV risk behavior; and transgender women engaging in any HIV risk behavior, a single item was used (e.g., “How willing are you to refer or link to PrEP…transgender females who engage in any HIV risk behavior?”). Response options were 1= Not at all; 2= Somewhat; 3= Very; 4= Extremely.
To assess provider willingness to refer/link: MSM; women who use opioids; and men who use opioids, four items were used (i.e., “How willing are you to refer or link to PrEP … MSM; women who use opioids; men who use opioids who: [1] inject drugs, [2] have condomless sex with multiple partners, [3] have HIV positive partners, and/or [4] exchange sex for money, drugs, or other things?”). Response options for each item were 1 = Not at all; 2 = Somewhat; 3 = Very; 4 = Extremely. The mean across the four items was calculated for: MSM (a = .98), men who use opioids (a = .97), and women who use opioids (a = .97).
Qualitative interview guide
The study team collaboratively developed a qualitative interview guide to cover constructs based on the Integrated Promoting Action on Research Implementation through Health Services (i-PARIHS) implementation science framework (Harvey & Kitson, 2015). We used this multi-level (structural, provider, and consumer level) framework to especially examine structural-level factors related to the need for, facilitators and barriers to, and proposed strategies for implementation of (1) referral for and linkage to local PrEP and opioid use services; and (2) on-site provision of PrEP and opioid use services. In the current study, we focus only on PrEP outcomes. The interview covered constructs across the range of i-PARIHS domains (i.e., recipients [e.g., PWUD], inner context [e.g., free-standing vs. system-integrated agencies); outer context [e.g., local and state-level policies impacting PrEP provision]; and implementation outcomes [e.g., innovative strategies to increase PrEP referral/linkage and/or onsite PrEP provision) (Harvey & Kitson, 2015). Directors could singularly provide accounts of their experiences, observations, and recommendations for implementation, based on agency-level (i.e., i-PARIHS inner context) and local/state (i.e., i-PARIHS outer context) factors pertaining to PrEP. Interviews gave directors a space to reflect on the context of the workplace in which providers came to express willingness to link and refer clients to PrEP. The context included the local and policy environment; and agency mission, resources, regulatory responsibilities, and operations (and workarounds).
We used an interview guide containing questions adapted from prior interviews in PrEP research from our group (Spector et al., 2015) and questions expressing major constructs from prior PrEP and opioid use services quantitative surveys (i.e., such as those being used for providers and consumers in this study). Within a formative phase at the start of the study, a systematic instrument development procedure was conducted. This included: (1) reviews by a panel of protocol development team experts and agency director advisors; (2) pilot testing the instrument with a few agency directors not participating in the current study; and (3) final revisions.
Data analyses
Quantitative data analyses
Descriptive statistics were used to describe provider sociodemographic characteristics and their PrEP awareness and experience. Paired t-tests were conducted to test statistically significant differences in provider willingness to refer/link different client populations to PrEP. To account for the nested data structure of multiple providers within a single site, a series of mixed-effects models were employed. For the continuous outcome variables (Table 4), we used linear mixed-effects models via PROC MIXED. The models included a random intercept for site. The fixed effects in the model were provider age, years of field experience, gender, race, ethnicity, education level, agency type, and position. These demographic and professional characteristics were treated as covariates in the model to assess their association with the outcome, while controlling for the influence of other variables.
Table 4.
Factors Associated with Provider Willingness to Refer/Link Different Clients at High Risk for HIV for PrEP (N = 191)
| Any Client | MSM | Trans Men | Trans Women | Men Who | Women Who | |
|---|---|---|---|---|---|---|
| Use Opioids | Use Opioids | |||||
| B (SE) | B (SE) | B (SE) | B (SE) | B (SE) | B (SE) | |
| (95% CI) | (95% CI) | (95% CI) | (95% CI) | (95% CI) | (95% CI) | |
| Intercept | 3.91 (0.27) *** | 3.64 (.31) *** | 3.55 (.32) *** | 3.55 (.32) *** | 3.62 (.31) *** | 3.61 (.32) *** |
| (3.31–4.51) | (2.94–4.34) | (2.83–4.27) | (2.84–4.27) | (2.93–4.30) | (2.91–4.32) | |
| Age | −.00 (.01) | −.00 (.01) | −.00 (.01) | −.00 (.01) | −.00 (.01) | −.00 (.01) |
| (−.01−.01) | (−.02−.01) | (−.02−.01) | (−.02−.01) | (−.02−.01) | (−.02−.01) | |
| Years of experience in field | .00 (.01) | .01 (.01) | .01 (.01) | .01 (.01) | .01 (.01) | .01 (.01) |
| (−.01−.02) | (−.01−.02) | (−.01−.03) | (−.01−.02) | (−.01−.32) | (−.01−.02) | |
| Gender (Female ref.) | −.01 (.11) | .09 (.12) | .12 (.13) | .11 (.12) | .09 (.12) | .12 (.12) |
| (−.22−.20) | (−.14−.33) | (−.12−.37) | (−.14−.35) | (−.15−.32) | (−.12−.36) | |
| Race (White ref.) | ||||||
| Black/African American | .02 (.10) | −.08 (.12) | −.12 (.12) | −.14 (.12) | −.10 (.12) | −.06 (.12) |
| (−.18−.22) | (−.31−.15) | (−.36−.12) | (−.38−.10) | (−.32−.13) | (−.29−.17) | |
| Other Race/Mixed | .13 (.16) | .25 (.18) | .24 (.19) | .22 (.19) | .29 (.18) | .29 (.18) |
| (−.18−.44) | (−.11−.60) | (−.13−.61) | (−.15−.58) | (−.06−.64) | (−.07−.65) | |
| Hispanic/Latine (Non-Hisp. ref.) | .06 (.14) | .14 (.17) | .25 (.17) | .23 (.17) | .09 (.16) | .11 (.17) |
| (−.23−.34) | (−.19−.47) | (−.09−.59) | (−.11−.57) | (−.23−.42) | (−.23−.44) | |
| Education (Graduate Degree ref.) | ||||||
| High School/GED | −.08 (.15) | .19 (.17) | .23 (.18) | .20 (.18) | .19 (.17) | .13 (.18) |
| (−.39−.22) | (−.15−.54) | (.−.13−.59) | (−.16−.56) | (−.15−.53) | (−.22−.48) | |
| College | −.04 (.12) | .02 (.14) | −.00 (.15) | −.02 (.15) | .03 (.14) | .03 (.14) |
| (−.29−.20) | (−.25−.30) | (−.29−.29) | (−.31−.27) | (−.25−.31) | (−.26−.31) | |
| Post-Graduate | .04 (.15) | .05 (.17) | .08 (.17) | .08 (.17) | .11 (.17) | .05 (.17) |
| (−.25−.34) | (−.28−.38) | (−.26−.43) | (−.26−.43) | (−.22−.43) | (−.28−.39) | |
| Agency Type (SSP ref.) | ||||||
| STI clinic | −.08 (.11) | .15 (.15) | .16 (.14) | .18 (.14) | .13 (.14) | .08 (.14) |
| (−.30−.15) | (−.14−.43) | (−.11−.45) | (−.10−.45) | (−.15−.41) | (−.28−.39) | |
| SUTP | −.57 (.14)*** | −.34 (.19) | −.35 (.18) | −.33 (.18) | −.35 (.18)* | −.33 (.18) |
| (−.85–−.29) | (−.72−.03) | (−.71−.00) | (−.68−.02) | (−.71–−.00) | (−.70−.03) | |
| Position Category (medical provider ref.) | ||||||
| Administrator/Research | .02 (.14) | −.02 (.16) | −.14 (.16) | −.10 (.16) | −.02 (.15) | .00 (.16) |
| (−.25−.29) | (−.33−.28) | (−.46−.19) | (−.42−.22) | (−.33−.28) | (−.31−.31) | |
| Behavioral Health Provider | −.22 (.13) | −.06 (.15) | −.12 (.16) | −.06 (.16) | −.03 (.15) | −.05 (.15) |
| (−.48−.05) | (−.36−.24) | (−.43−.20) | (−.38−.25) | (−.33−.27) | (−.35−.26) | |
| Care Coordinator/Linkage | −.20 (.13) | −.28 (.15) | −.27 (.16) | −.22 (.16) | −.29 (.15) | −.30 (.15) |
| (−.46−.06) | (−.58−.02) | (−.58−.04) | (−.54−.09) | (−.59−.01) | (−.61−.00) |
p < .001;
p < .01;
p < .05.
For the binary outcomes (Table 5), we used generalized linear models with a binomial distribution and a logit link function, implemented via PROC GENMOD with a REPEATED statement. This approach, known as a Generalized Estimating Equation (GEE) model, accounts for the clustered data by specifying site as the subject for repeated measures, using a compound symmetric covariance structure to model the within-site correlation. The model included the same set of provider-level covariates as the linear mixed model.
Table 5.
Factors Associated with Providers’ Prior Experience Discussing and Referring Clients for PrEP
| Variable | PrEP Discussion Experience | PrEP Referral Experience | ||
|---|---|---|---|---|
| OR | (95% CI) | OR | (95% CI) | |
| Age | .96 | (.92 −.99) * | .98 | (.95 – 1.01) |
| Years of experience in field | 1.04 | (1.01 – 1.07) ** | .99 | (.95 – 1.02) |
| Gender (Female ref.) | 1.59 | (.92 – 2.78) | 1.00 | (.57 – 1.76) |
| Race (White ref.) | ||||
| Black/African American | .52 | (.25 – 1.06) | .68 | (.32 – 1.43) |
| Other Race/Mixed | .29 | (.06 – 1.41) | .44 | (.10 – 1.95) |
| Hispanic/Latine (Non-Hisp. ref.) | .26 | (.02 – 1.26) | .09 | (.01 – 1.24) |
| Education (Graduate Degree ref.) | ||||
| High School/GED | 4.13 | (.63 – 27.08) | 1.68 | (.49 – 5.80) |
| College | 1.18 | (.37 – 3.81) | .55 | (.21 – 1.45) |
| Post-Graduate | 1.60 | (.53 – 4.80) | .85 | (.46 – 1.56) |
| Agency Type (SSP ref.) | ||||
| STI clinic | .83 | (.20 – 3.51) | .66 | (.25 – 1.77) |
| SUTP | .06 | (.02 – .20) *** | .17 | (.06 – .48) *** |
| Position Category (medical provider ref.) | ||||
| Administrator/Research | 1.10 | (.37 – 3.29) | 3.51 | (.89 – 13.87) |
| Behavioral Health Provider | .45 | (.15 – 1.29) | .59 | (.16 – 2.13) |
| Care Coordinator/Linkage | .76 | (.25 – 2.29) | .61 | (.21 – 1.76) |
p < .001;
p < .01;
p < .05.
Prior to model fitting, multicollinearity among the predictor variables was assessed by examining the Variance Inflation Factor (VIF) for each variable using a standard linear regression model. All VIFs were below the recommended threshold of 5, suggesting that multicollinearity was not a significant concern. For linear fixed effects models, we report the parameter estimates and standard errors along with their 95% confidence intervals. Significant p-values are indicated in bold and by asterisks (*p < .05, **p < .01, ***p < .001). Odds ratios (OR) and 95% confidence intervals (CI) are presented for the GEE model.
Because we did not compare nested models or compare models on the same data set, we do not present model fit (e.g., AIC, BIC, QIC). Linear mixed-effects models and generalized linear models Tables 4 and 5 are regression models on different subgroups. All analyses were conducting using SAS 9.4 (SAS Institute, 2016).
Qualitative data analyses
Three study team members (MPW, ST, and MME) developed a codebook based on the qualitative interview guide. Qualitative interviews were digitally audio-recorded, transcribed, and entered in Atlas.ti v9® for coding and analysis using an iterative process. An initial codebook covered the topics and subtopics of the interview guide. Two coders then systematically marked text segments for the presence of codes that expressed major constructs and sub-constructs and identified illustrative quotations. The initial codebook was used to code the first two interviews and was expanded and revised as additional codes emerged during the coding process. The two coders separately coded these interviews, discussed their respective coding rationales, and resolved any discrepant coding in consensus discussions. All interviews were double-coded, using the same process.
Data were analyzed using a framework analytic approach (Gale et al., 2013). This approach involved charting codes for every participant; identifying emergent overarching themes and sub-themes; mapping the co-occurrence of themes and sub-themes and their clustering in particular participant subgroups (e.g., STI clinic, SSP, and SUTP directors); and interpreting these analyses.
Qualitative results are presented by themes related to the i-PARIHS framework (see Figure 2). Within each theme in the main text, data are first described as all-site explanatory results; second, by type-of-site explanatory results; and third, by any site-specific variations. We highlight distinct contextual factors across sites that could have facilitated or impeded provider willingness to refer/link clients to PrEP, and which could have implications for PrEP implementation.
Figure 2.

Qualitative Results Within the i-PARIHS Framework
Results – quantitative
Provider demographic characteristics
Forty-five percent of the providers who completed the survey worked in STI clinics, 31% in SSPs, and 24% in SUTPs. Position categories included medical providers (28%), behavioral health providers (27%), care coordinators/linkage (25%), and administrators/researchers (20%). Additional demographic characteristics can be found in Table 1.
Table 1.
Provider Characteristics (N = 191)
| N or M | % or SD | Range | |
|---|---|---|---|
| Age (M, SD) | 40.42 | 11.44 | 23–75 |
| Years of Experience in the Field (M, SD) | 9.70 | 9.65 | 0–42 |
| Gender (N, %) a | |||
| Cisgender Male | 59 | 30.89 | |
| Cisgender Female | 132 | 69.11 | |
| Race (N, %) | |||
| Black | 83 | 44.15 | |
| White | 86 | 45.74 | |
| Multiracial/Other | 19 | 10.11 | |
| Ethnicity (N, %) | |||
| Non-Hispanic/Latine | 165 | 87.30 | |
| Hispanic/Latine | 24 | 12.70 | |
| Education (N, %) | |||
| High School/GED | 25 | 13.09 | |
| College | 59 | 30.89 | |
| Graduate Degree | 83 | 43.46 | |
| Post-graduate Degree | 24 | 12.57 | |
| Agency Type (N, %) | |||
| Syringe Services Program | 60 | 31.41 | |
| STI Clinic | 85 | 44.50 | |
| Substance Use Treatment Program | 46 | 24.08 | |
| Position Category (N, %) | |||
| Administrator/Researcher | 39 | 20.42 | |
| Medical Provider | 53 | 27.75 | |
| Behavioral Health Provider | 52 | 27.23 | |
| Care Coordinator/Linkage | 47 | 24.61 |
Provider PrEP awareness and experience
Almost all (95%) of the providers had heard of PrEP. Of those, most had previously initiated a conversation with a client about PrEP (63%) and had referred a client for PrEP (65%) (Table 2).
Table 2.
Provider PrEP Awareness and Experience (N = 191)
| N | % | |
|---|---|---|
| Heard of PrEP | ||
| No | 10 | 5.24 |
| Yes | 181 | 94.76 |
| Had previously initiated PrEP conversation with a client | ||
| No | 67 | 37.02 |
| Yes | 114 | 62.98 |
| Had previously referred a client for PrEP | ||
| No | 63 | 34.81 |
| Yes | 118 | 65.19 |
Comparison of provider mean willingness to refer/link different clients at high risk for HIV to PrEP
Table 3 presents the results of the paired t-tests. For all client types, providers expressed considerably high levels of willingness to refer/link to PrEP – with all means falling between the Very and Extremely Willing anchor ratings. However, providers were significantly more willing to refer/link a client with high HIV risk to PrEP (population group unspecified; M = 3.68, SD = .62) compared to transgender men (M = 3.57, SD = .73; t(190) = 2.18, p = .031), transgender women (M = 3.58, SD = .72; t(190) = 1.98, p = .049), men who use opioids (M = 3.57, SD = .70; t(190) = 2.20, p = .029), and women who use opioids (M = 3.56, SD = .71; t(190) = 2.46, p = .015). However, no difference in willingness to refer/link was found between clients with high HIV risk (population group unspecified) compared to MSM. Further, providers were significantly more willing to refer/link MSM to PrEP (M = 3.59, SD = .70) compared to women who use opioids (M = 3.56, SD = .71; t(190) = 2.59, p = .010).
Table 3.
Comparison of Provider Mean Willingness to Refer/Link Different Clients at High Risk for HIV to PrEP (N = 191)
| Paired t-tests | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M a | SD | vs. MSM | vs. TM | vs. TW | vs. MO | vs. WO | ||||||
| t(190) | p | t(190) | p | t(190) | p | t(190) | p | t(190) | p | |||
| Any Client with High HIV Risk | 3.68 | .62 | 1.83 | .068 | 2.18 | .031 | 1.98 | .049 | 2.20 | .029 | 2.46 | .015 |
| MSM | 3.59 | .70 | -- | 1.02 | .311 | .58 | .565 | 1.70 | .091 | 2.59 | .010 | |
| Transgender Men (TM) | 3.57 | .73 | -- | -- | −1.00 | .319 | −.19 | .853 | .37 | .708 | ||
| Transgender Women (TW) | 3.58 | .72 | -- | -- | -- | .34 | .733 | .89 | .374 | |||
| Men Who Use Opioids (MO) | 3.57 | .70 | -- | -- | -- | -- | 1.32 | .190 | ||||
| Women Who Use Opioids (WO) | 3.56 | .71 | -- | -- | -- | -- | -- | |||||
Note.
1 = Not at all to 4 = Extremely.
Correlates of provider willingness to refer/link different clients at high risk for HIV to PrEP
Table 4 shows the results of the linear mixed effects models for willingness to refer/link PrEP to a client with high HIV risk (population group unspecified), MSM, transgender men, transgender women, men who use opioids, and women who use opioids. Of the eight correlates included in the models, only agency type was significantly associated with willingness for two types of clients: Providers working in SUTPs were significantly less willing than those in SSPs to refer/link a client with high HIV risk (population group unspecified; B =−.57, SE = .14, p < .001) and men who use opioids, to PrEP (B =−.35, SE = .18, p < .05). No other significant factors emerged for any of the other client groups.
Correlates of providers’ prior experience talking with clients about PrEP and referring clients at risk for HIV for PrEP
Table 5 shows the results of the non-linear mixed effects model results. Of the eight correlates examined, age, tenure in the field, and agency type were significantly associated with prior experience talking with clients about PrEP, and agency type correlated with providers having talked about and referred clients to PrEP. No other variables were significantly associated with either outcome. Older vs. younger providers had lower odds (OR = .96, CI = .92–.99) of having previously talked with clients about PrEP. Providers with more vs. fewer years of experience in the field had greater odds (OR = 1.04, CI = 1.01–1.07) of having previously talked with clients about PrEP. Providers working in SUTPs, compared to SSPs, had lower odds (OR = .06, CI = .02–.20) of having previously talked with clients about PrEP and lower odds (OR = .17, CI = .06–.48) of having previously referred clients for PrEP.
Results – qualitative
Themes from directors’ views underlying predominant provider willingness
There were five salient themes from directors’ views of facilitators underlying provider willingness to link clients to PrEP, described in detail below. Themes are summarized in Table 6 and linked to the i-PARIHS framework in Figure 2.
Table 6.
Qualitative Interview Themes Summary
| Directors’ Views Underlying Facilitators of Provider Willingness to refer/link to PrEP | |
|---|---|
| Themes | Description of Themes |
| 1. HIV Prevention is an Integral Part of the Mission for All Sites | Directors deemed HIV risk assessment and testing; risk reduction education; and referral to HIV prevention, care, and treatment services as essential components of their programs, with some site variations: within SSPs, immediate, day-to-day substance use-driven and subsistence stressors were priorities over PrEP. |
| 2. Sites Have Procedures for PrEP Education and Linkage | Ranged from formal policies part of HIV testing and STI screening (STI clinics; SUTPs; SSPs) to no formal policies (some SSPs. |
| 3.On-Site PrEP Services Available in Sites That Were Co-Located Within Comprehensive Community Health Centers or Had Active Partnerships with Outside Agency Medical Services | Sites with collaborative agreements with nearby sites; part of federally qualified health centers (FQHCs); or part of one-stop, comprehensive health service entities (e.g., sites that offered primary medical care, HIV testing, and substance use treatment in one location) were particularly well-positioned to offer PrEP screening, information, and linkage (if not on-site) services for clients, as well as PrEP training for providers. |
| 4. Staffing of PrEP Services with Navigators and People with Lived Experience is a Facilitator of PrEP Willingness | Dedicated navigators—who conduct HIV risk assessments, provide PrEP education, link patients to medical providers for PrEP prescription, facilitate PrEP payment assistance, and conduct PrEP follow-up—were observed to make the PrEP experience more real and feasible for clients and providers |
| 5. Directors Held a Generally Wide-Net View of Who Was Eligible for PrEP | |
| Themes of Directors’ Views Underlying Provider Hesitancy or Inconsistency in Willingness to refer/link to PrEP | |
| Themes | Description of Themes |
| 1. PWUD, Especially Those Who Inject Drugs, Are Perceived as Unable to Adhere to PrEP | Directors cited here-and-now, life-and-death health and safety concerns as urgent priorities (e.g., the primacy of drug hunger, drug use, intoxication, and obtaining one’s day-to-day drugs) as impeding clients’ engagement with PrEP. All directors noted that providers held especially negative opinions of and reluctance to offer PrEP services to PWUD, and particularly PWID. |
| 2. Some Regional Cultural Norms Serve as Barriers to Provide PrEP Services to MSM | Directors described regional cultural norms rejecting same-sex or same-gender sexual relationships; abstinence-only sex education in schools; policies criminalizing sex between people living with HIV and seronegative partners as major deterrents to the open discussion of sexual practices essential in introducing PrEP. |
| 3.Provider Willingness to Provide PrEP Services May Be Diminished by Lack of Funds and Resources | Lack of funding limited PrEP coverage for clients and constrained the hiring of new staff to support PrEP programing. |
| 4. Provider Willingness to Provide PrEP Services May Be Deterred by Staff Burnout, Particularly Under the Constraints Of COVID-19 Pandemic | Staff strain related to increased workload under COVID-19 pandemic conditions and difficulty adjusting to pandemic-related telehealth systems noted as significant barriers to PrEP implementation. |
Theme 1: HIV prevention is an integral part of the mission for all sites
All sites, regardless of type, identified HIV prevention as an integral part of their agency missions, for which they had received funding. Directors deemed HIV risk assessment and testing; risk reduction education; and referral to HIV prevention, care, and treatment services as essential components of their programs. In all agency types, HIV risk reduction information, testing, and referral for services constituted sound platforms for introducing PrEP. Moreover, all agency types were community-based human services-dedicated organizations that were deeply committed to improving health and quality of life for their clients. However, there were differences in the salience of these priorities and the degree to which they were being implemented between STI clinics and SUTPs, on the one hand, and SSPs, on the other. All STI clinic sites were highly involved in promoting PrEP, and even at the forefront of providing PrEP services in their geographic areas. The five STI clinic directors identified PrEP services as top agency priorities. For example, one STI clinic director (i.e., in the free-standing LGBTQ+ youth-centered CBO) stated, “We were the first organization in [city name] to offer PrEP for uninsured young people, Black and brown young people, and gay and trans women.”
Directors of SUTPs within well-established, multi-site substance use treatment agencies, similarly stated: “I think [PrEP] is incredibly important. Our patients, especially with what we are dealing with on a regular basis, are those patients that we absolutely should be having conversations with [about PrEP].” In contrast, although all SSP directors viewed PrEP as a priority, they emphasized the role of immediate, day-to-day substance use-driven and subsistence stressors as competing, and often, overriding priorities for their clients. As one director of a freestanding SSP explained:
“Every single thing we do out there is saving lives, so I wouldn’t say that the [HIV prevention and treatment] referrals are any more [of a priority] … I think it’s very important, and I guess at the end of the day … when you look at our vision and mission statements … our number one goal is to stop the spread of infectious diseases.”
Theme 2: Sites have procedures for PrEP education and linkage
In accordance with their missions, all sites had routine procedures for PrEP education and linkage; however, there were differences in the intensity and scope of these procedures by agency type. For STI clinics, PrEP education and screening readily fit with routine HIV risk assessment and testing practices. Identification of HIV seronegative status triggered providers to share information with clients about PrEP, its purpose, conditions for use, and circumstances under which it could be offered (i.e., on-site or linkage to other community sites). Based on established partnerships with medical clinics, linkages were often highly streamlined, resulting in immediate PrEP appointments and navigator-assisted participation. Four of five STI clinics included in the qualitative analyses provided PrEP services on-site, in one of three ways: (1) via their own staff at the STI clinic; (2) at their co-located agency medical clinic; or (3) via visiting Department of Health staff at the STI clinic.
SUTP directors also described HIV risk assessment and testing, discussion of sexuality, HIV prevention, and PrEP education as regular components of comprehensive medical and behavioral screening and counseling within substance use treatment. One director emphasized: “All my staff that are clinicians or medical providers … We have to do a sexual risk assessment with every single patient that walks in the door … We worked so hard on training and cultural diversity … Substance abuse goes hand-in-hand with the [HIV transmission] risk of sexual behavior.”
All five SSP directors described having PrEP education and linkage to off-site PrEP services and staff training for education and linkage. Four SSPs had county, state, and/or federally funded HIV testing and prevention programs, and these SSP directors described PrEP education as a ready part of HIV testing already in place. Still, procedures for screening and linkage—and the extent to which they were systematically implemented—varied across SSPs. One freestanding SSP had “no formal policy,” but “does warm hand-offs” to PrEP services. Another freestanding SSP routinely “passes out those TelePrEP cards. When a person is interested in PrEP, they are linked to a PrEP delivering agency.” Another SSP, an academic medical center-based SSP involved in research on integrated substance use and HIV/HCV medical services for PWUD, offered on-site PrEP screening, medication, and follow-up services.
Theme 3: On-site PrEP services available in sites that were co-located within comprehensive community health centers or had active partnerships with outside agency medical services
Regardless of agency type, presence of either co-located medical services or active partnership with nearby medical services distinguished those sites that were able to offer on-site PrEP services. Sites who were part of federally qualified health centers (FQHCs) or one-stop, comprehensive health service entities (e.g., primary medical care, HIV testing, and substance use treatment in one location) were particularly well-positioned to offer PrEP services (i.e., screening, information, linkage [if not on-site]) for clients; PrEP training for providers). Alternatively, some sites had active “collaborative agreements” with nearby medical services. SUTP directors described especially helpful support from dedicated grants for HIV testing and prevention services for people receiving substance use treatment. Grants were from Substance Abuse and Mental Health Services Administration (SAMHSA), CDC, state and local health departments, and other state and local entities.
Theme 4: Staffing of PrEP services with navigators and people with lived experience is a facilitator of PrEP willingness
Across all sites, staffing with PrEP navigators and people with lived experience were perceived to be promoters of PrEP interest and motivation among clients and providers. Navigators’ work included conducting HIV risk assessments, providing PrEP education, linking patients to medical providers for PrEP prescription, facilitating PrEP payment assistance, and conducting PrEP follow-up. Navigators were observed to make the PrEP experience more real and feasible for both clients and providers. As exemplified by one STI clinic director (i.e., of a site within a large HIV testing and prevention agency), navigators engaged in a series of follow-up steps following PrEP linkage:
“We do have PrEP navigators in place who will call clients and check on them and say—especially [for] those who are newly on PrEP: ‘We know that you’ve made it through your first seven days. Are you having any problems? Do you need to come in and see the provider?’ That’s the same process for those people where we’re waiting on their lab work. So if we find something a little ‘eh’ with the lab work, we tell them, ‘Hey, we’ve scheduled an appointment. Come on back in. We want to just go over some things with you.’ If everything is fine, we let them know, ‘Hey, you can pick your PrEP prescription up here at the clinic, CVS, or Walgreens. Do you have a preference?’”
SSP directors emphasized that employing staff with lived experiences like those of their clients is a key facilitator to PrEP implementation: “I think [clients] feel positive about [PrEP] because … [our staff is] reflective of the population that we serve. We are people, real positive people who are [or] have been on PrEP, MSMs, the LGBT people who’ve been on drugs … anything along that line.”
Theme 5: Directors held a generally wide-net view of who was eligible for PrEP
Quantitative results suggested that providers’ willingness to refer/link clients to PrEP varied depending on the client population. Yet, qualitative director interview results generally indicated that all sites (regardless of agency type) defined the PrEP eligible population widely, while putting special emphasis on individuals with high HIV risk. Thus, an STI clinic director noted that “PrEP is always on the table as a conversation.” Another director described having a “diverse clientele. We saw an influx of white males in our clinic once we started providing PrEP. Now that’s about balanced out. We have women, Black MSM, white MSM, as well as trans women, who are all serviced by our PrEP program.”
SUTP directors perceived their patient populations as especially vulnerable to HIV, and thus perceived PrEP to be an essential component of their services. One SUTP director explained:
“You’re talking about individuals who are actively using substances, actively engaging in risky behaviors that put them at high risk for things like HIV. I can’t think of a better population that you would be having those services for. These adults are at the highest risk.”
SSP directors also described PrEP eligibility in broad terms, as encompassing individuals at risk for HIV due to injection drug use or male-to-male sexual activity, as well as different-sex sexual activity.
Themes from directors’ views underlying provider hesitancy or inconsistency in willingness
The director qualitative interviews also provided an understanding of contextual barriers to willingness to provide PrEP services; these barriers may, in part, explain differences in provider willingness to link different types of consumers to PrEP found in the quantitative data. There were four salient themes as described below (see also, Table 6 and Figure 2):
Theme 1: PWUD, especially those who inject drugs, are perceived as unable to adhere to PrEP
While directors expressed profound concern for the daily survival struggles of PWUD, for the same reason, they also tended perceive PWUD as lacking the motivation or capability to take PrEP. Some directors cited here-and-now, life-and-death health and safety concerns as urgent priorities (e.g., the primacy of hunger, drug use, intoxication, and obtaining drugs to prevent withdrawal symptoms) as impeding clients’ engagement with PrEP. One SSP director of a freestanding SSP explained: “A lot of our clientele are intoxicated, so you know, it’s hard to reach them. It’s hard to get them to stay still. When the monster is calling you, it’s hard to hear a voice of reason.” Another SSP director, of the research SSP, observed:
“Yes, I think [drugs are] the biggest thing … Really, it has to do with the priorities of having to inject something 10 or 15 times a day and spending hundreds and hundreds of dollars every day … So I think that is just the priorities of [their] next dose versus thinking about anything else.”
All directors noted that providers held especially negative opinions of and reluctance to offer PrEP services to PWUD, and particularly PWID. Directors at STI clinics, SSPs, and SUTPs lamented staff’s stigmatizing biases against PWUD and PWID and reluctance to prescribe them PrEP. For example, one STI clinic director (i.e., of a site within a large community health center) described staff mistrust of PWID, whom they perceived as being at high risk for HIV but unable to adhere to PrEP:
“ … I know that a priority should be persons who engage in injection drug use, but I think that we have this idea—not I think, I know—we have this idea about that demographic, that they’re not going to be able to keep up with medication and not worried about, you know, like they need to stop taking drugs … They don’t need to necessarily support them in [injecting drugs] in a safer manner. It’s not ideal … “
Another SSP director observed a relative neglect of PWUD and PWID in PrEP campaigns in his community. He explained: “After the rollout [of PrEP campaigns] … there were posters everywhere, almost all geared to MSM … nice looking young Latino guy taking PrEP.”
Relatedly, SUTP directors indicated that staff lacked knowledge about the scope of PrEP need among their treatment populations. Staff in SUTPs also held stigmatizing perceptions of client behaviors associated with HIV and thus rejected the value of PrEP for clients perceived as “willing” to engage such behaviors. One director observed:
“[Some providers would question:] ‘What the—why would we [offer PrEP]? Why don’t we just educate? Why don’t we just prevent?’ … Well, why would we be giving this medication? … [Staff] have the same response to PrEP as they have for medication-assisted [OUD] treatment. It’s like, ‘Ah. Why would we do that?’”
Theme 2: Some regional policies and concomitant cultural norms serve as barriers to providing PrEP services to MSM
Some directors, particularly those in STI clinics, described regional policies and concomitant cultural norms rejecting same-sex or same-gender sexual relationships that impacted the delivery of services to MSM. They also cited abstinence-only sex education in schools and state laws criminalizing sex between people living with HIV (PLWH) and seronegative partners as two major deterrents to the open discussion of sexual practices essential in introducing PrEP. These observations suggest the possible role of some regional cultural norms as inhibiting providers’ willingness to provide PrEP services to these populations. In fact, one STI clinic director described only being able to provide PrEP services to men if categorized as “reproductive health services.” This director observed:
“The only policy that remotely even addresses anything around PrEP is the provision of reproductive health services … So PrEP falls under reproductive health services. But I can’t say that our state has caught up with the idea of even PrEP. There is no legislative law or policy that you can go and look up anything around PrEP. Actually, in this state, HIV can be criminalized … If you are knowingly HIV positive and you are having sex and not notify your partner of your status, then it can be criminalized.”
Another bemoaned the inability to connect minors to PrEP services, sadly stating: “I share stories about the kids that seroconverted, tested [HIV] positive on their 18th birthday because they were withheld PrEP.”
Theme 3: Provider willingness to provide PrEP services may be diminished by lack of funds and resources
A common structural-level barrier cited across all sites was lack of funding, which not only limited coverage for clients but also constrained the hiring of new staff to support PrEP programming. One SUTP director, while mindful of pharmaceutical company medication assistance funding for individuals, highlighted the lack of funding for provider services around PrEP, required laboratory services, or other needed medications. This director stated:
“I think the biggest barriers [to PrEP] are funding. I think it’s 100% funding. There is a patient assistance program. But again, if you don’t have the resources to get the reimbursement for these services, the patient assistance program isn’t helpful because there is no reimbursement for the agent services associated with it. And if that patient is unfunded, then what ends up happening is that then there are no resources for the labs that are required. There’s [sic] no resources for the other medications that they need to stay to be maintained … and we don’t have the same type of contracting that is associated with some of the infectious disease and all of that.”
This director also cited the strain that high co-pays and deductibles put on clients with private insurance.
Theme 4: Provider willingness to provide PrEP services may be deterred by staff burnout, particularly under the constraints of the COVID-19 pandemic
Directors at all agencies noted staff strain related to increased workload under COVID-19 pandemic conditions (e.g., difficulty adjusting to pandemic-related telehealth systems) as significant barriers to PrEP implementation. For example, the SSP director of the research SSP described his staff as “being pulled in different directions.” This director also noted that due to the COVID-19 pandemic and associated precautionary policies, PrEP activities that did not require physical examination or procedures were conducted via telehealth. In two SSP sites, conversations to initiate PrEP, schedule lab testing, and conduct follow-ups for refills and education about adherence took place through telehealth.
Discussion
In community programs in Southern U.S. cities, this study gathered quantitative data on providers’ willingness to link and refer clients at high risk for HIV to PrEP, coupled with qualitative in-depth interviews with site directors on factors underlying PrEP willingness and hesitancy. Quantitative findings demonstrated that even in resource- and policy-constraining environments and regions, providers can develop a high level of willingness to refer/link clients to PrEP. Still, we found that several factors may inhibit providers’ willingness, including differential stigma toward certain client groups. Qualitative interviews informed our understanding of structural and macro-level (e.g., state and local policies; program procedures) influences on provider willingness. Together, quantitative and qualitative findings offer insight into barriers, facilitators, and strategies for enhancing PrEP implementation within Southern U.S. CBOs. In doing so, this study addresses gaps in the extant literature regarding PrEP service delivery among PWUD in the Southern U.S., a population with relatively low PrEP uptake and high HIV incidence.
Provider PrEP awareness and experience
Provider surveys revealed that nearly all providers had heard of PrEP, had previously initiated a conversation with a client about PrEP, and had referred a client for PrEP. These findings suggest higher PrEP willingness among participating CBO providers (both prescribers and non-prescribers) in the Southern U.S. vs. prior research indicating lower willingness among PrEP-prescribing providers (Jones et al., 2021; Petroll et al., 2017; Walsh & Petroll, 2017). Directors’ identification of HIV testing and prevention as major components of their agency missions and regular services provided a useful contextual explanation for the nearly universal PrEP awareness and experience among providers. All directors described offering some form of PrEP education, screening, HIV testing and PrEP linkage—albeit with wide variation. These services were also cited as major reasons for funding from local, state, or federal HIV prevention or services initiatives.
Provider willingness to refer/link different clients at high risk for HIV to PrEP
Providers were more willing to refer/link any client (regardless of population group) with wide-ranging HIV risk factors to PrEP compared to transgender women, transgender men, and cisgender people who used opioids, but not compared to MSM. These findings may be due to providers’ perceived competencies working with various clientele. For example, a Tennessee-based survey study found that PrEP providers (including those who could and could not prescribe PrEP) felt the least skilled and least comfortable in discussing sexual behavior with transgender clients compared to other client groups (Moore et al., 2020). Such discomfort can lead to missed opportunities for linking transgender clients to PrEP. These findings call attention to the importance of offering education and training opportunities to increase provider competence in working with transgender clients and PWUD (Nyblade et al., 2019).
Our finding that providers were significantly more willing to refer/link MSM to PrEP than cisgender women who used opioids implies that providers still view MSM as the target population for PrEP over other populations with HIV risk. Indeed, directors observed that the PrEP public health and pharmaceutical messaging and marketing in their communities was overwhelmingly tailored for MSM. Findings echo those in a prior qualitative study conducted in Alabama; although providers were open to referring and linking cisgender Black women clients to PrEP, they still perceived PrEP as primarily directed toward MSM (Waldron et al., 2024). A previous survey study, however, found that providers were significantly more willing to offer PrEP both to MSM (like our study) and transgender women (vs. heterosexual people with multiple partners) (Mullins et al., 2017). These contradictory findings suggest a need for future research focused more specifically on provider PrEP willingness with transgender and cisgender women.
Provider survey data also demonstrated lower willingness to refer/link men and women who use opioids to PrEP services. Directors also observed hesitancy with PWUD (particularly PWID). Directors attributed this hesitancy to frequent provider perceptions that PWUD are facing daily, often crisis-level struggles with addiction and survival that impede adherence to PrEP regimens and follow-up. These observations echo survey results from a prior study with primary care providers working in clinics with high substance use and HIV prevalence. These clinics reported that 88% of providers demonstrated implicit bias toward PWID, and considered them poor candidates for PrEP due to perceived inability to adhere to medication and routine follow-up (Dubov et al., 2023).
Other recent studies have also documented provider stigma and biases as well as reluctance to prescribe PrEP to PWUD in general (Campbell et al., 2018), and specifically PWID (Dubov et al., 2023; Waldron et al., 2024). For example, a recent review paper attributed this reluctance to provider bias and lack of cultural competence regarding PWUD life experience and sensibility (Biello et al., 2021). A survey of 142 HIV providers in Miami, Florida, and Washington, D.C., found that providers with less experience implementing PrEP were also less willing to prescribe PrEP to PWUD (Castel et al., 2015).
Lower provider PrEP willingness toward PWUD also raised the prospect of another attitudinal barrier – risk compensation (i.e., the perception that taking PrEP may encourage behaviors associated with HIV transmission risk) (Dubov et al., 2023; Turner et al., 2018). Some Directors described marked reluctance in providers to give medication they viewed as enabling risk behavior, in lieu of intervening to help clients reduce or eliminate risk behavior. A 2021 review highlighted provider bias and low cultural sensitivity as barriers to implementing PrEP (Biello et al., 2021). These findings emphasize a need for additional provider training to reduce stigmatizing misconceptions and enhance culturally tailored practice with the populations like those in this study.
Correlates of provider willingness to refer/link different clients at high risk for HIV to PrEP
We also found that SUTP providers were significantly less willing than SSP providers to link cisgender men who used opioids, reiterating potential biases against referring/linking PWUD to PrEP. SUTP (vs. SSP) providers also had significantly lower odds of having previously spoken with clients about or having previously referred clients to PrEP. These results suggest that SUTPs might be a point of intervention to support PrEP implementation. SUTPs should, in theory, be an ideal setting in which to refer/link clients to PrEP and could present opportunities for a one-stop model (Biello et al., 2021).
Correlates of providers’ prior experience talking with clients about PrEP and referring clients at risk for HIV for PrEP
Our findings that older providers and those with more years of experience echo those of a previous study (N = 519 providers) in which older age correlated with lower PrEP prescribing, while more vs. less training correlated with greater prescribing (Leech et al., 2020). We posit that field experience aligns more closely with PrEP amenability than age given the proximity of time in the field to PrEP introduction and availability in 2012 (Baeten et al., 2012). Such providers may have experienced higher (and possibly more nuanced) exposure to PrEP knowledge, anecdotal experience, more PrEP positive norms, and potentially more PrEP training opportunities. Age may not imply an increase in PrEP knowledge, training, or exposure. In fact, we speculate that older age might indicate belonging to a cohort for whom HIV prevention was anchored in risk reduction behavior, suspicion about the “risk compensation” potential of PrEP use, and lower connection and excitement to late-breaking PrEP developments.
Implications for strategies to promote PrEP provider willingness and referral/linkage in community programs
Together, the quantitative and, especially, qualitative results highlight actionable ways to further promote PrEP implementation and provider willingness to refer/link to PrEP services in CBOs like those in the current study. Our findings are consistent with existing literature that emphasizes a need for a multilevel approach for enhancing PrEP implementation facilitators (e.g., conducting staff training and support) and reducing PrEP implementation barriers (e.g., providing PrEP payment assistance; co-locating services) (Frank et al., 2022).
Five strategies for enhancing provider willingness to refer/link clients to PrEP are directly indicated within our study findings. First, as expressed in both provider survey and director interview findings, comprehensive staff training programs—explicitly focused on enhancing recognition of implicit bias and capacity for culturally competent services, and tailored to populations at high risk for HIV risk—are imperative. Both quantitative and qualitative findings highlight lack of familiarity with the lived experiences of transgender individuals as well as stigmatizing beliefs that the lives of PWUD (especially PWID) are too unstable to initiate, much less adhere to PrEP regimens.
Provider stigma toward PWUD and transgender populations may be linked to providers viewing drug use and transgender identities as “immoral”; blaming clients for their challenges with substance use and behavior that elevates HIV risk; and providers’ fear of PWUD, transgender people, or HIV infection (Nyblade et al., 2019). In a recent systematic review, strategies to address these barriers include: providers receiving education about the stigmatized condition (e.g., drug use as a brain disorder; PrEP as a highly effective strategy for preventing HIV transmission) to improve knowledge and reduce implicit biases; providers engaging in practical training activities to build skills for working with PWUD and transgender clients (e.g., clinical rotations); providers having opportunities for communication and engagement with PWUD and transgender clients to reduce stereotypes; and healthcare organizations instituting structural changes and policies for agency practice that would improve equitable access to services for stigmatized groups (Nyblade et al., 2019). Further, in formulating strategies for PrEP implementation in the South, Sullivan et al. (2019) emphasize the benefits of using health-empowering (i.e., “gain-framing”), rather than fear-arousing (i.e., “loss-framing”), messaging—both for PrEP promotion and stigma reduction.
Second, as expressed in directors’ accounts, employing PrEP-dedicated peer navigators with lived experiences like those of the populations served can be a powerful antidote to negative beliefs toward individuals at high risk for HIV. Further, with appropriate allocation of time and effort, these navigators can more readily carry out rigorous PrEP client follow-up with outside agencies than can staff with full workloads in other core services (Reback et al., 2019; Salabarrıa-Pena et al., ~ 2022). Navigators are thus both a uniquely effective workforce, in and of themselves, and could also offset the intense work-strain and vulnerability to burnout among other agency staff.
Third, as also expressed in directors’ accounts, sites within one-stop, all-inclusive health service entities (especially FQHCs), or with collaborative partnerships with such agencies, are better prepared to offer PrEP linkage or onsite PrEP services. Previous research has similarly noted high acceptability of co-located PrEP, substance use, and health services among PWUD (Bartholomew et al., 2022; Frank et al., 2022). In contrast, other studies have observed that without all-inclusive services, linkage to PrEP outside the referring agency is extremely challenging due to clients’ competing immediate survival needs (Biello et al., 2018; Chan et al., 2024; Ni et al., 2021). In resource-constrained settings in the South, having one-stop and/or collaborative services may be especially important to promote PrEP implementation (Sullivan et al., 2019).
Fourth, some directors identified the imperative to use workarounds or creative problem-solving to integrate HIV prevention into non-HIV services, particularly in regions where policies stigmatized same-sex/same-gender relationships and people living with HIV, and schools focused on abstinence-only sex education in schools. One director’s strategy to overcome these constraints included offering PrEP under the “reproductive health” umbrella. Other sites, however, were limited by state policies preventing PrEP provision to minors.
Fifth, all directors described securing funding as a priority for supporting all the above-described PrEP implementation strategies. All described constant pursuit of grant funding, as grants were their principal avenue for financial support. Some directors in states that had declined Medicaid expansion cited advocacy and lobbying as important strategies to obtain funding. Some described taking steps with pharmaceutical companies to initiate so-called “430b” Drug Pricing Programs to purchase discounted PrEP and reinvest associated savings into other CBO services. In their review, Sullivan et al. (2019) described initiatives between entities in Southern states and Northeastern states to obtain funding from the PrEP Patient Assistance Program (PrEP-AP) or other governmental resources to fund PrEP for the uninsured or underinsured clients.
Through this array of strategies, our findings echo existing literature that emphasize a need for a multilevel approach to enhance PrEP implementation facilitators and to address PrEP implementation barriers. Such strategies include staff training and support and co-located services (Frank et al., 2022).
Limitations and strengths
The current study addresses gaps in the extant literature regarding provider attitudes toward referring and linking PWUD to PrEP in the Southern U.S., a region with high rates of HIV and drug-related overdose. There are several limitations in this study. First, there is the potential for social desirability bias in the self-reported data from provider surveys. Second, because participants were recruited from CBOs within urban areas, results may not generalize to rural settings in the Southern U.S. PrEP is generally less accessible in rural, compared to urban areas, particularly in the South (Kamitani et al., 2024; Siegler et al., 2018). A prior study (which included the Southern state of Georgia) reported that only 12% of facilities offering PrEP were in rural locations, compared to 88% in urban settings (Siegler et al., 2018). Additionally, rural localities may experience unique structural barriers to PrEP that differ from those identified in the current urban-centric study (Kamitani et al., 2024). For example, a recent study found that rural pharmacies were less likely than urban pharmacies to stock PrEP, thus limiting the availability of same-day PrEP prescription and initiation (Kislovskiy et al., 2024).
Third, although our sample draws from cities with high HIV incidence and thus higher need for PrEP, our results may not generalize to urban locations in other Southern states given that Medicaid expansion varies widely (Thompson & Southern Poverty Law Project, 2025). States that have not adopted Medicaid expansion may not cover additional costs of taking PrEP (e.g., lab tests), thus limiting PrEP accessibility for individuals with fewer economic resources (Srikanth et al., 2022).
Fourth, we made the decision to exclude the 12 providers who identified as TGNB from the final data analysis due to the small sample size of this subgroup. Inclusion of TGNB providers would have led to statistically underpowered and potentially unreliable comparisons, while also posing a risk to participant anonymity. This exclusion introduces potential for sampling bias and further limits the generalizability of our findings. The perspectives of TGNB providers on the care of transgender clients are uniquely valuable and likely differ in significant ways from those of their cisgender colleagues. TGNB providers may have lived experiences that inform their clinical practice and attitudes, potentially leading to different training needs, practice patterns, and empathy and understanding toward TGNB clients (Paschen-Wolff et al., 2024). To overcome this limitation in the future, studies should employ targeted recruitment strategies, such as partnering with TGNB professional organizations and community groups.
Fifth, although directors were generally aware of staff willingness regarding PrEP referral/linkage, qualitative interviews with directors may not have captured more nuanced provider attitudes toward PrEP. Finally, as a mixed methods study that included a cross-sectional survey with providers as well as one-time in-depth qualitative interviews with site directors, our findings cannot address temporal changes in policies or offering of services at these sites. Future research should examine structural and policy-level barriers and facilitators over time to understand the impact on local and state-level provision of PrEP. Notwithstanding limitations, this study used an innovative mixed methods approach to help discern barriers and facilitators of PrEP implementation in CBOs in a region of the country with significant disparities in HIV by race, ethnicity, and gender identity. Study findings shed light on viable opportunities to enhance provision of PrEP in CBOs as highly effective settings for reaching populations at high risk for HIV.
Conclusion
Our mixed methods study revealed generally high willingness among Southern community providers to refer/link PWUD to PrEP, with a focus on clients at high risk for HIV and particularly MSM. Both quantitative and qualitative findings demonstrate that willingness varied by client type, with stigma directed toward PWUD, specifically people who use opioids and inject drugs. Director interviews contextualized quantitative findings regarding provider willingness, indicating that organizational and structural factors like agency policies and procedures, availability of funding and PrEP-dedicated staff, and regional norms around sexuality influenced staff attitudes toward PrEP. These findings point to the importance of bolstering structural support for PrEP referral/linkage (e.g., being part of a comprehensive medical center; funding for PrEP-dedicated staff) in PrEP promotion and reduction of PrEP disparities, particularly among PWUD in the Southern U.S.
Acknowledgments
We gratefully acknowledge the enormous contribution and dedication of all the clients, providers, and directors in participating study sites, who tirelessly worked to conduct the study during the height of the COVID-19 pandemic. We also acknowledge the significant contribution of Brenda Stuvek, BS, University of Washington Addictions, Drug & Alcohol Institute and Department of Psychiatry & Behavioral Sciences Program Operations Specialist, and Node Coordinator of the Pacific Northwest Node of the NIDA Clinical Trials Network. Ms. Stuvek performed all fiscal oversight and responsibilities for this multi-site study.
Funding
This study was supported by grants from the National Institute on Drug Abuse (NIDA) National Drug Abuse Treatment Clinical Trials Network: UG1DA013035, New York, NY, PIs: John Rotrosen (NYU School of Medicine) and Edward Nunes (Columbia University Irving Medical Center & NY State Psychiatric Institute); UG1DA013714, Seattle, WA, PIs: Mary Hatch (University of Washington) and John Roll (Washington State University). This study was also supported by NIDA under contract numbers 75N95020D00012 (Clinical Coordinating Center, the Emmes Company) and HHSN271201400028C (Data and Statistics Center, the Emmes Company). Melissa Ertl was supported by Award Number T32 MH019139 (PI: Theodorus Sandfort, Ph.D.) from the National Institute of Mental Health (NIMH) and Award Number R25 DA050687-01A1 (PI: Avelardo Valdez, Ph.D.) from NIDA and the National Institute on Alcohol Abuse and Alcoholism (NIAAA). This study was also supported by a center grant from the NIMH to the HIV Center for Clinical and Behavioral Studies at Columbia University (P30-MH43520; PI: Robert Remien). Landhing Moran was substantially involved in UG1DA013035 and UG1DA013714, consistent with her role as Scientific Officer.
Footnotes
Disclosure statement
The authors report there are no competing interests to declare.
Data availability statement
The data that support the findings of this study are available from Mary Hatch, PhD, the lead investigator of this study (via e-mail: hatch@uw.edu) upon reasonable request.
References
- AIDSvu. (2024a). Deeper look: PrEP. https://aidsvu.org/resources/deeper-look-prep/
- AIDSvu. (2024b). Southern HIV/AIDS awareness day toolkit 2024. https://aidsvu.org/toolkit-southern-hiv-aids-awareness-day-2024/
- Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, & Katabira E (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New England Journal of Medicine, 367(5), 399–410. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bartholomew TS, Andraka-Cristou B, Totaram RK, Harris S, Doblecki-Lewis S, Ostrer L, Serota DP, Forrest DW, Chueng TA, & Suarez E (2022). “We want everything in a one-stop shop”: acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs. Harm Reduction Journal, 19(1), 133. 10.1186/s12954-022-00721-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Biello K, Bazzi A, Mimiaga M, Biancarelli D, Edeza A, Salhaney P, Childs E, & Drainoni M (2018). Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduction Journal, 15, 1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Biello KB, Mimiaga MJ, Valente PK, Saxena N, & Bazzi AR (2021). The past, present, and future of PrEP implementation among people who use drugs. Current HIV/AIDS Reports, 18(4), 328–338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Castel AD, Feaster DJ, Tang W, Willis S, Jordan H, Villamizar K, Kharfen M, Kolber MA, Rodriguez A, & Metsch LR (2015). Understanding HIV care provider attitudes regarding intentions to prescribe PrEP. JAIDS Journal of Acquired Immune Deficiency Syndromes, 70(5), 520–528. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Centers for Disease Control and Prevention. (2017a). HIV surveillance report. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
- Centers for Disease Control and Prevention. (2017b). National HIV Behavior Surveillance (NHBS). https://www.cdc.gov/hiv/statistics/systems/nhbs/index.html
- Centers for Disease Control and Prevention. (2021). US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: A clinical practice guideline. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
- Centers for Disease Control and Prevention. (2023). HIV surveillance report, 2021; Vol. 34. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html [Google Scholar]
- Centers for Disease Control and Prevention. (2025). Clinical guidance for PrEP. HIV Nexus: CDC Resources for Clinicians. https://www.cdc.gov/hivnexus/hcp/prep/index.html [Google Scholar]
- Chan K, Mitchell MM, Casselle E, & Bender AA (2024). Facilitators and barriers to PrEP acceptability and initiation among opioid treatment program patients and staff. AIDS Education and Prevention, 36(1), 60–72. [DOI] [PubMed] [Google Scholar]
- Creswell JW, Plano Clark VL, Gutmann ML, & Hanson WE (2003). Advanced mixed methods research designs. In Tashakkori A & Teddlie C (Eds.), Handbook of Mixed Methods in Social and Behavioral Research (pp. 209–240). SAGE. [Google Scholar]
- Dawson L, Kates J, Roberts T, & Chidambaram P (2023). Medicaid and people with HIV. https://www.kff.org/hivaids/issue-brief/medicaid-and-people-with-hiv/
- Dubov A, Krakower DS, Rockwood N, Montgomery S, & Shoptaw S (2023). Provider implicit bias in prescribing HIV pre-exposure prophylaxis (PrEP) to people who inject drugs. Journal of General Internal Medicine, 38(13), 2928–2935. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ertl MM, Woodhouse C, Meche D, Forrest DW, Fegley J, Paschen-Wolff M, Laschober TC, Hatch MA, Nelson CM, & Wright L (2025). Using structural equation modeling to examine barriers and facilitators of HIV pre-exposure prophylaxis willingness and length of use in men who have sex with men who use substances in eight Southern US cities. AIDS Patient Care and STDs, 39(6), 245–256. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Frank L, Starzyk E, Hoxworth T, Canon M, McGuinness C, Watkins A, Deem T, & Orozco-Pacheco G (2022). HIV PrEP implementation: A multi-level systems approach. Evaluation and Program Planning, 90, 101966. [DOI] [PubMed] [Google Scholar]
- Gale NK, Heath G, Cameron E, Rashid S, & Redwood S (2013). Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Medical Research Methodology, 13, 1–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Harvey G, & Kitson A (2015). PARIHS revisited: From heuristic to integrated framework for the successful implementation of knowledge into practice. Implementation Science, 11, 1–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hatch MA, Laschober TC, Paschen-Wolff M, Ertl MM, Nelson CM, Wright L, Lancaster C, Feaster DJ, Forrest D, & Hankey C (2024). PrEP for people who use opioids: A NIDA Clinical Trials Network survey study in southern US cities where HIV incidence is high. Drug and Alcohol Dependence, 111133. 10.1016/j.drugalcdep.2024.111133 [DOI] [PMC free article] [PubMed] [Google Scholar]
- HIV.gov. (2024). Pre-exposure prophylaxis. https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/pre-exposure-prophylaxis
- Jaiswal J, Dunlap K, Griffin M, Cox A, Singer S, Hascher K, LoSchiavo C, Walters S, & Mumba M (2021). Pre-exposure prophylaxis awareness, acceptability and potential stigma among medical and non-medical clinic staff in methadone treatment settings in northern New Jersey: The key role of non-medical staff in enhancing HIV prevention. Journal of Substance Abuse Treatment, 129, 108371. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones JT, deCastro BR, August EM, & Smith DK (2021). Pre-exposure prophylaxis (PrEP) awareness and prescribing behaviors among primary care providers: DocStyles survey, 2016–2020, United States. AIDS and Behavior, 25, 1267–1275. [DOI] [PubMed] [Google Scholar]
- Kamitani E, Mizuno Y, & Koenig LJ (2024). Strategies to eliminate inequity in PrEP services in the US South and Rural communities. Journal of the Association of Nurses in AIDS Care, 35(2), 153–160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kates J, Dawson L, Horn TH, Killelea A, McCann NC, Crowley JS, & Walensky RP (2021). Insurance coverage and financing landscape for HIV treatment and prevention in the USA. The Lancet, 397(10279), 1127–1138. [DOI] [PubMed] [Google Scholar]
- Kislovskiy Y, Pino N, Crawford ND, Woitas T, Cason S, Konka A, Kimble T, Olson I, Villarreal D, & Jarlenski M (2024). Pre-exposure and postexposure prophylaxis access in rural versus urban pharmacies in Georgia and Pennsylvania. Journal of the American Pharmacists Association, 64(4), 102084. [DOI] [PubMed] [Google Scholar]
- Leech AA, Christiansen CL, Linas BP, Jacobsen DM, Morin I, & Drainoni M-L (2020). Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. PloS One, 15(9), e0238375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mimiaga MJ, Case P, Johnson CV, Safren SA, & Mayer KH (2009). Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. JAIDS Journal of Acquired Immune Deficiency Syndromes, 50(1), 77–83. 10.1097/QAI.0b013e31818d5a27 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Moore E, Kelly SG, Alexander L, Luther P, Cooper R, Rebeiro PF, Zuckerman AD, Hargreaves M, Bourgi K, & Schlundt D (2020). Tennessee healthcare provider practices, attitudes, and knowledge around HIV pre-exposure prophylaxis. Journal of Primary Care & Community Health, 11, 2150132720984416. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mullins TLK, Zimet G, Lally M, Xu J, Thornton S, Kahn JA, & Interventions, A. M. T. N. f. H. A. (2017). HIV care providers’ intentions to prescribe and actual prescription of pre-exposure prophylaxis to at-risk adolescents and adults. AIDS Patient Care and STDs, 31(12), 504–516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ni Z, Altice FL, Wickersham JA, Copenhaver MM, DiDomizio EE, Nelson LE, & Shrestha R (2021). Willingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment. Drug and Alcohol Dependence, 219(219), 108477. 10.1016/j.drugalcdep.2020.108477 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nyblade L, Stockton MA, Giger K, Bond V, Ekstrand ML, Lean RM, Mitchell EM, Nelson LRE, Sapag JC, & Siraprapasiri T (2019). Stigma in health facilities: Why it matters and how we can change it. BMC Medicine, 17, 1–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Paschen-Wolff MM, DeSousa A, Paine EA, Hughes TL, & Campbell AN (2024). Experiences of and recommendations for LGBTQ+-affirming substance use services: An exploratory qualitative descriptive study with LGBTQ+ people who use opioids and other drugs. Substance Abuse Treatment, Prevention, and Policy, 19(2), 1–20. 10.1186/s13011-023-00581-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, & Kelly JA (2017). PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS and Behavior, 21, 1256–1267. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reback CJ, Clark KA, Rünger D, & Fehrenbacher AE (2019). A promising PrEP navigation intervention for transgender women and men who have sex with men experiencing multiple syndemic health disparities. Journal of Community Health, 44, 1193–1203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Salabarría-Peña Y, Douglas C, Brantley M, & Johnson AK (2022). Informing the future of PrEP navigation: findings from a five-site cluster evaluation. Evaluation and Program Planning, 90, 101999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- SAS Institute, I. (2016). SAS® 9.4 Language Reference: Concepts, Sixth Edition. SAS Institute, Inc. Cary, NC [Google Scholar]
- Siegler AJ, Bratcher A, Weiss KM, Mouhanna F, Ahlschlager L, & Sullivan PS (2018). Location location location: An exploration of disparities in access to publicly listed pre-exposure prophylaxis clinics in the United States. Annals of Epidemiology, 28(12), 858–864. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Spector AY, Remien RH, & Tross S (2015). PrEP in substance abuse treatment: A qualitative study of treatment provider perspectives. Substance Abuse Treatment, Prevention, and Policy, 10, 1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sprague C, & Simon SE (2021). Ending HIV in the USA: Integrating social determinants of health. The Lancet, 398(10302), 742–743. [DOI] [PubMed] [Google Scholar]
- [Record #110 is using a reference type undefined in this output style.]
- Sullivan PS, Mena L, Elopre L, & Siegler AJ (2019). Implementation strategies to increase PrEP uptake in the South. Current HIV/AIDS Reports, 16, 259–269. [DOI] [PMC free article] [PubMed] [Google Scholar]
- The White House. (2021). National HIV/AIDS Strategy for the United States 2022–2025. https://www.hiv.gov/federal-response/national-hiv-aidsstrategy/
- Thompson GA, & Southern Poverty Law Project. (2025). Stepping into the gap: Medicaid expansion in the deep south as a lifeline to care. https://www.splcenter.org/resources/reports/medicaid-expansion-deep-south/
- Traylor DO, Enriquez M, Thompson-Robinson M, Yu M, Bloom T, & Bullock L (2024). Barriers and facilitators that influence HIV Pre-exposure Prophylaxis (PrEP)-prescribing behaviors among primary care providers in the Southern United States. Cureus, 16(8), e66868. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tross S, Laschober TC, Paschen-Wolff M, Ertl M, Nelson CM, Wright L, Lancaster C, Feaster DJ, Monger M, & Toal P (2025). Willingness to use oral and long-acting injectable prep in substance-using men who have sex with men (SU-MSM) in high HIV incidence southern US cities: A NIDA Clinical Trials Network study. AIDS and Behavior, 29(4), 1192–1204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Turner L, Roepke A, Wardell E, & Teitelman AM (2018). Do you PrEP? A review of primary care provider knowledge of PrEP and attitudes on prescribing PrEP. Journal of the Association of Nurses in AIDS Care, 29(1), 83–92. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vanhamel J, Rotsaert A, Reyniers T, Nöstlinger C, Laga M, Van Landeghem E, & Vuylsteke B (2020). The current landscape of pre-exposure prophylaxis service delivery models for HIV prevention: A scoping review. BMC Health Services Research, 20, 1–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Waldron EM, Goodman GR, Rivas AM, Ott C, Blyler A, McDonald VW, Campbell M, Underwood E, Bonner A, & Wise JM (2024). Perceptions of and preferences for PrEP use among African American women and providers in the US South: A qualitative study. Psychology & Health, 1–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Walsh JL, & Petroll AE (2017). Factors related to pre-exposure prophylaxis prescription by US primary care physicians. American Journal of Preventive Medicine, 52(6), e165–e172. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available from Mary Hatch, PhD, the lead investigator of this study (via e-mail: hatch@uw.edu) upon reasonable request.
